Based on the evidence from the single studies and the absence of concrete modifications in BC patient management guided by PSMA-targeted PET/CT, this novel diagnostic examination cannot be suggested as an alternative to standard-of-care imaging. The gene discussed is FOLH1; the disease is breast cancer.